NIKKEI 225
39,038.16 +354.23 (+0.92%) HANG SENG
18,366.95 -109.85 (-0.59%) CRUDE OIL
77.89 +2.36 (+3.12%) GOLD FUTURES
2,328.90 +3.90 (+0.17%) DOW
38,831.62 +32.63 (+0.08%) Bitcoin GBP
54,729.75 -12.45 (-0.02%)
REPL Aug 2024 10.000 put
- Zacks
Replimune (REPL) Gains on Positive Data From Melanoma Study
Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.
- GlobeNewswire
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:00 PM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com.
- Benzinga
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat several types of cancer. The results show that one-third of patients receiving RP1 plus nivolumab responded to treatment, improving upon the investigator-assessed data presented at ASCO 2024. All resp
